These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

540 related items for PubMed ID: 28535616

  • 1. Drug-induced osteonecrosis of the jaw: the state of the art.
    Fassio A, Bertoldo F, Idolazzi L, Viapiana O, Rossini M, Gatti D.
    Reumatismo; 2017 May 22; 69(1):9-15. PubMed ID: 28535616
    [Abstract] [Full Text] [Related]

  • 2. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
    Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Dabagh RA, Davison KS, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J, International Task Force on Osteonecrosis of the Jaw.
    J Clin Densitom; 2017 May 22; 20(1):8-24. PubMed ID: 27956123
    [Abstract] [Full Text] [Related]

  • 3. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
    Loyson T, Van Cann T, Schöffski P, Clement PM, Bechter O, Spriet I, Coropciuc R, Politis C, Vandeweyer RO, Schoenaers J, Dumez H, Berteloot P, Neven P, Nackaerts K, Woei-A-Jin FJSH, Punie K, Wildiers H, Beuselinck B.
    Acta Clin Belg; 2018 Apr 22; 73(2):100-109. PubMed ID: 28693379
    [Abstract] [Full Text] [Related]

  • 4. Antiresorptive treatment-associated ONJ.
    Eleutherakis-Papaiakovou E, Bamias A.
    Eur J Cancer Care (Engl); 2017 Nov 22; 26(6):. PubMed ID: 29063702
    [Abstract] [Full Text] [Related]

  • 5. Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis.
    Everts-Graber J, Lehmann D, Burkard JP, Schaller B, Gahl B, Häuselmann H, Studer U, Ziswiler HR, Reichenbach S, Lehmann T.
    J Bone Miner Res; 2022 Feb 22; 37(2):340-348. PubMed ID: 34787342
    [Abstract] [Full Text] [Related]

  • 6. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
    Dodson TB.
    Oral Maxillofac Surg Clin North Am; 2015 Nov 22; 27(4):509-16. PubMed ID: 26362367
    [Abstract] [Full Text] [Related]

  • 7. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
    Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Stürzenbaum S, Pautke C.
    J Craniomaxillofac Surg; 2012 Jun 22; 40(4):303-9. PubMed ID: 21676622
    [Abstract] [Full Text] [Related]

  • 8. Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan.
    Liu FC, Luk KC, Chen YC.
    Osteoporos Int; 2023 Oct 22; 34(10):1729-1737. PubMed ID: 37326685
    [Abstract] [Full Text] [Related]

  • 9. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.
    Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J, International Task Force on Osteonecrosis of the Jaw.
    J Bone Miner Res; 2015 Jan 22; 30(1):3-23. PubMed ID: 25414052
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Osteonecrosis of the jaw].
    Drozdzowska B.
    Endokrynol Pol; 2011 Jan 22; 62 Suppl 3():4-9. PubMed ID: 22161980
    [Abstract] [Full Text] [Related]

  • 12. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B, Drudge-Coates L, Ali S, Pati J, Nargund V, Ali E, Cheng L, Wells P.
    Urol Nurs; 2016 Jan 22; 36(3):111-6, 154. PubMed ID: 27501591
    [Abstract] [Full Text] [Related]

  • 13. The Risk of Medication-Related Osteonecrosis of the Jaw in Children: Guidance for Antiresorptive Use in Pediatric Patients.
    Lasky S, Moshal T, Shakoori P, Roohani I, Jolibois M, Youn S, Urata MM, Hammoudeh JA.
    J Oral Maxillofac Surg; 2024 Oct 22; 82(10):1285-1294. PubMed ID: 38950582
    [Abstract] [Full Text] [Related]

  • 14. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
    Svejda B, Muschitz Ch, Gruber R, Brandtner Ch, Svejda Ch, Gasser RW, Santler G, Dimai HP.
    Wien Med Wochenschr; 2016 Feb 22; 166(1-2):68-74. PubMed ID: 26847441
    [Abstract] [Full Text] [Related]

  • 15. Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden.
    Ehrenstein V, Heide-Jørgensen U, Schiødt M, Akre O, Herlofson BB, Hansen S, Larsson Wexell C, Nørholt SE, Tretli S, Kjellman A, Glennane A, Lowe KA, Sørensen HT.
    Cancer; 2021 Nov 01; 127(21):4050-4058. PubMed ID: 34310704
    [Abstract] [Full Text] [Related]

  • 16. Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab.
    Yarom N, Lazarovici TS, Whitefield S, Weissman T, Wasserzug O, Yahalom R.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jan 01; 125(1):27-30. PubMed ID: 29102242
    [Abstract] [Full Text] [Related]

  • 17. Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw.
    Higuchi T, Soga Y, Muro M, Kajizono M, Kitamura Y, Sendo T, Sasaki A.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jun 01; 125(6):547-551. PubMed ID: 29574058
    [Abstract] [Full Text] [Related]

  • 18. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
    Ghidini G, Manfredi M, Giovannacci I, Mergoni G, Sarraj A, Mureddu M, Giunta G, Bonanini M, Meleti M, Vescovi P.
    Minerva Stomatol; 2017 Aug 01; 66(4):135-140. PubMed ID: 28497661
    [Abstract] [Full Text] [Related]

  • 19. Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis.
    Voss PJ, Steybe D, Poxleitner P, Schmelzeisen R, Munzenmayer C, Fuellgraf H, Stricker A, Semper-Hogg W.
    Odontology; 2018 Oct 01; 106(4):469-480. PubMed ID: 29713913
    [Abstract] [Full Text] [Related]

  • 20. What is the Risk of Developing Osteonecrosis Following Dental Extractions for Patients on Denosumab for Osteoporosis?
    Colella A, Yu E, Sambrook P, Hughes T, Goss A.
    J Oral Maxillofac Surg; 2023 Feb 01; 81(2):232-237. PubMed ID: 36442534
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.